Abstract
Most studies examining the causes of cancer-related deaths have primarily focused on specific cancer types, often neglecting the evolving spectrum of death causes among cancer patients in the 21st century. This study, utilizing data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, analyzed the causes of death in patients diagnosed with 36 types of cancer between 2000 and 2021. By categorizing these causes into deaths from index cancers, non-index cancers, and non-cancer causes, this study provides a comprehensive analysis of cause-of-death patterns and emerging trends, stratified by year of death, age at diagnosis, and survival duration. The findings reveal that while relative mortality rates from index cancers remain elevated for brain, pancreatic, and gallbladder cancers, significant declines were observed for lung, liver, nasopharyngeal, and esophageal cancers, as well as multiple myeloma cancers, reflecting advancements in cancer treatment. Besides, relative mortality rates from non-index cancers surpassed those from index cancers in oral cavity, oropharyngeal, vaginal, and small intestine cancers, indicating a potential benefit from enhanced surveillance and early detection of non-index cancers in these patient populations. Importantly, non-cancer-related causes of death, such as heart disease, chronic liver disease and cirrhosis, also emerged as prominent contributors to mortality among cancer patients. The results of this study offer critical and current data to inform public health policy, optimize healthcare resource allocation, and facilitate international collaboration in cancer research and control. Meanwhile, this study is of great reference value for developing countries to formulate medium– and long-term public health policies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Natural Science Foundation of China (81602167; 82372617 and 81972658; 81803636), the Hunan Provincial Natural Science Foundation of China (2017JJ3494 and 2021JJ31100), the Open Project of Xiangjiang Laboratory (23XJ03001), the Science and Technology Program Foundation of Changsha City (kq2004085), the Fundamental Research Funds for the Hunan Provincial Innovation Foundation for Postgraduate (CX20230328), the Guangdong Basic and Applied Basic Research Foundation (2024B1515020090 and 2023A1515012683; 2024A1515030038; 2023B1212060013 and 2020B1212030004), and the Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan (2024A03J0845 and 2023A04J2098). In addition, we appreciate laboratory members for thoughtful suggestions and comments on the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://seer.cancer.gov/data-software/documentation/seerstat/nov2021/. The data were obtained from the Surveillance, Epidemiology, and End Results (SEER) program. Specifically, this study utilized cancer patient data from the SEER 17 registry and the SEER 8 registry, which can be accessed through the SEER*Stat software (version 8.4.3). The SEER program provides publicly available data via their official website, where interested researchers can request access and download the data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
https://seer.cancer.gov/data-software/documentation/seerstat/nov2021/
